# Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions

> **NCT00875966** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 42 (actual)

## Conditions studied

- Infections

## Interventions

- **DRUG:** Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC
- **DRUG:** Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer

## Key facts

- **NCT ID:** NCT00875966
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00875966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00875966, "Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00875966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*